The NIH-sponsored trial will help inform decisions about vaccine approval for 12- to 17-year-olds.
The investigational vaccine is in the third phase of trials and targets flu strains expected to circulate this winter.
Encouraging immune-response and safety data emerge from preliminary human test of genetically attenuated parasite vaccine.
Participant in KPWHRI trial receives world’s first-ever injection of investigational SchistoShield vaccination.
NIAID-sponsored study includes Seattle in test for benefits of mixing different vaccine types.
An investigational vaccine developed by Moderna is being tested for safety and immune response in Seattle and 3 other cities.
Lisa Jackson, MD, MPH, Kaiser Permanente Washington senior investigator, recounts the genesis of a groundbreaking vaccine.
Our Seattle offices sit on the occupied land of the Duwamish and by the shared waters of the Coast Salish people, who have been here thousands of years and remain. Learn about practicing land acknowledgment.